非妊娠青少年和成人乙型肝炎病毒筛查:USPSTF更新证据报告与系统综述
无研究直接评估筛查对临床结局的影响;抗病毒治疗与改善中间结局相关,可能改善临床结局但证据有限。
要点
- 无直接证据比较乙肝筛查与不筛查对死亡率、肝癌或肝硬化的影响。
- 基于风险因素(如高流行国家移民)的筛查策略可识别几乎所有乙肝感染病例。
- 抗病毒治疗与更高的病毒学抑制和HBeAg血清学转换率相关。
核心结论
- 无直接证据表明乙肝筛查与不筛查相比的临床获益和危害。
- 抗病毒治疗与改善中间结局相关,可能改善临床结局但数据稀疏且不精确。
研究设计与样本
- 检索Cochrane图书馆和Ovid MEDLINE(2014年至2019年8月),监测至2020年7月24日。
- 采用随机效应轮廓似然meta分析。
主要发现
- 无研究直接评估筛查对死亡率、肝细胞癌或肝硬化的影响。
- 基于18项试验(n=2972),抗病毒治疗相比安慰剂或无治疗与更高的中间结局达标率相关,需治疗人数从病毒学抑制的2.6到HBeAg血清学转换的17。
- 基于12项试验(n=4127),一线抗病毒治疗在达到中间结局方面至少不劣于非首选治疗。
- 基于16项试验(n=4809),抗病毒治疗可能改善临床结局,但数据稀疏且不精确。
关键数值与推荐
- 筛查策略聚焦风险因素如曾从高流行国家移民、人口学和行为风险因素可识别几乎所有乙肝感染病例。
- 基于18项试验(n=2972),抗病毒治疗达到中间结局的需治疗人数:病毒学抑制为2.6,HBeAg血清学转换为17。
临床怎么用
- 基于风险因素的筛查策略可能识别大多数乙肝感染病例。
- 抗病毒治疗可改善中间结局,但临床结局获益证据有限。
- 需权衡抗病毒治疗的不良事件退出风险。
局限性
- 无直接评估筛查与不筛查对临床结局影响的研究。
- 抗病毒治疗对临床结局影响的证据稀疏且不精确。
- 队列研究异质性大,风险比范围宽(0.07至0.87)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: A 2014 review for the US Preventive Services Task Force (USPSTF) found antiviral therapy for hepatitis B virus (HBV) infection associated with improved intermediate outcomes, although evidence on clinical outcomes was limited. OBJECTIVE: To update the 2014 HBV screening review in nonpregnant adolescents and adults to inform the USPSTF. DATA SOURCES: Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, and Ovid MEDLINE (2014 to August 2019); with surveillance through July 24, 2020. STUDY SELECTION: Randomized clinical trials (RCTs) on screening and antiviral therapy; cohort studies on screening, antiviral therapy clinical outcomes, and the association between achieving intermediate outcomes after antiviral therapy and clinical outcomes. DATA EXTRACTION AND SYNTHESIS: One investigator abstracted data; a second investigator checked accuracy. Two investigators independently assessed study quality. Random-effects profile likelihood meta-analysis was performed. RESULTS: Thirty trials and 20 cohort studies, with a total of 94 168 participants, were included. No study directly evaluated the effects of screening for HBV infection vs no screening on clinical outcomes such as mortality, hepatocellular carcinoma, or cirrhosis. Screening strategies that focused on risk factors such as ever having immigrated from high-prevalence countries and demographic and behavioral risk factors would identify nearly all HBV infection cases. In 1 study (n = 21 008), only screening immigrants from high-prevalence countries would miss approximately two-thirds of infected persons. Based on 18 trials (n = 2972), antiviral therapy compared with placebo or no treatment was associated with greater likelihood of achieving intermediate outcomes, such as virologic suppression and hepatitis B e-antigen (HBeAg) or hepatitis B surface antigen loss or seroconversion; the numbers needed to treat ranged from 2.6 for virologic suppression to 17 for HBeAg seroconversion. Based on 12 trials (n = 4127), first-line antiviral therapies were at least as likely as nonpreferred therapies to achieve intermediate outcomes. Based on 16 trials (n = 4809), antiviral therapy might be associated with improved clinical outcomes, but data were sparse and imprecise. Nine cohort studies (n = 3893) indicated an association between achieving an intermediate outcome following antiviral therapy and improved clinical outcomes but were heterogeneous (hazard ratios ranged from 0.07 to 0.87). Antiviral therapy was associated with higher risk of withdrawal due to adverse events vs placebo or no antiviral therapy. CONCLUSIONS AND RELEVANCE: There was no direct evidence for the clinical benefits and harms of HBV screening vs no screening. Antiviral therapy for HBV infection was associated with improved intermediate outcomes and may improve clinical outcomes.
引用
- Chou R, Blazina I, Bougatsos C, et al. Screening for Hepatitis B Virus Infection in Nonpregnant Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2020. PMID: 33320229. doi:10.1001/jama.2020.19750
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。